• Company
• Reimb. to be expanded for PARP inhibitor Lynparza and Zejula
• by Eo, Yun-Ho Aug 13, 2021 05:58am

• Opinion
• [Reporter's view] Unstable supply of imported vaccines
• by Lee, Tak-Sun Aug 13, 2021 05:58am

• Company
• Alvogen is targeting patents for Roche's Avastin
• by Kim, Jin-Gu Aug 13, 2021 05:58am

• Policy
• “Mooncare a success…37 million people saved ₩9 tril.
• by Lee, Jeong-Hwan Aug 13, 2021 05:57am

• Policy
• Regkirona's indication expansion has been requested
• by Lee, Tak-Sun Aug 13, 2021 05:57am

• Company
• SGLT-2 inhibitor Forxiga lands in Korea with CKD indication
• by Eo, Yun-Ho Aug 12, 2021 06:05am

• Policy
• With Ultomiris, 9 items require prior approval for reimb.
• by Lee, Hye-Kyung Aug 12, 2021 06:05am

• Policy
• A review of Hemlibra's benefit without ITI is under way
• by Lee, Hye-Kyung Aug 12, 2021 06:05am

• Policy
• President called for stronger health insurance coverage
• by Kang, Shin-Kook Aug 12, 2021 06:04am

• Company
• Eybelis can be prescribed at general hospitals
• by Eo, Yun-Ho Aug 11, 2021 05:58am